Expert Review of Vaccines最新文献_第6页

Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework. 重庆市老年人流感疫苗接种意愿及其影响因素：基于WHO疫苗接种框架的行为和社会驱动因素的横断面研究

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-02 DOI: 10.1080/14760584.2026.2638826

Jule Yang, Shuang Yang, Yu Xiong, Baisong Li, Xiaoqing Fu, Mengmeng Jia, Li Qi

{"title":"Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework.","authors":"Jule Yang, Shuang Yang, Yu Xiong, Baisong Li, Xiaoqing Fu, Mengmeng Jia, Li Qi","doi":"10.1080/14760584.2026.2638826","DOIUrl":"10.1080/14760584.2026.2638826","url":null,"abstract":"Background: In the context of China's aging population and low influenza vaccine coverage, this study applied the Behavioral and Social Drivers (BeSD) framework to investigate the willingness and determinants of influenza vaccination among adults aged ≥60 years in Chongqing.Research design and methods: We designed a cross-sectional survey targeting the community population and collected data on willingness toward demographic and influenza vaccination through questionnaires. Descriptive analysis, logistic regression analyses were used to summarize the data and identify the possible factors of vaccination willingness.Results: Among 1617 participants, 46.9% (95%CI: 44.5-49.3) expressed willingness to receive influenza vaccines. Individuals aged ≥80 years (aOR = 1.51, 95%CI: 1.10-2.08) and having basic medical insurance for urban employees (aOR = 2.21, 95%CI: 1.69-2.90) were more likely to receive influenza vaccination. Participants who lived in rural areas (aOR = 0.38, 95%CI: 0.39-0.50) were more likely to experience vaccine hesitancy. Concerning the BeSD framework, concern of worsening health condition (74.43%) and concern of disrupted daily life (69.76%) were the primary and secondary concerns, whereas perceived high vaccine cost (54.95%) was identified as a major reason for hesitancy.Conclusions: This study further highlighted that psychological determinants, thinking and feeling are the most influential of vaccine acceptance and hesitancy.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2638826"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus. 从负担到受益：克服成人免疫障碍，重点是呼吸道合胞病毒。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-06-17 DOI: 10.1080/14760584.2026.2684962

Cláudia Vicente, Filipe Froes, Pier Luigi Lopalco, Catherine Heffernan, Ramin Nilforooshan, Friederike Martin, Isabel Leroux-Roels, Lior Nesher, Thomas Déplanque, Nidhi Dani, Ana Coelho, Nuno Pinto de Castro, Kayhan Tayarani-Binazir

{"title":"From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus.","authors":"Cláudia Vicente, Filipe Froes, Pier Luigi Lopalco, Catherine Heffernan, Ramin Nilforooshan, Friederike Martin, Isabel Leroux-Roels, Lior Nesher, Thomas Déplanque, Nidhi Dani, Ana Coelho, Nuno Pinto de Castro, Kayhan Tayarani-Binazir","doi":"10.1080/14760584.2026.2684962","DOIUrl":"10.1080/14760584.2026.2684962","url":null,"abstract":"Introduction: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection, with substantial morbidity and mortality in older adults, yet its impact in this population remains underrecognized compared with childhood RSV. Despite the availability of effective vaccines, RSV immunization in adults is underutilized, as observed for other vaccines.Areas covered: We summarize the RSV burden in adult populations and present clinical and real-world evidence supporting efficacy/effectiveness and safety of three approved RSV vaccines. We explore barriers to adult vaccine uptake - including limited awareness, lack of reimbursement, mistrust, misinformation, and inconsistent guidance - and highlight broader benefits of adult immunization, including reducing antimicrobial resistance and promoting healthy aging. We conclude that to improve uptake, communication strategies should include messages that emphasize how vaccination prevents severe illness, preserves independence, and supports everyday well-being. We highlight that a life-course immunization strategy, built on trust, is essential to achieve equitable protection across populations.Expert opinion: Adult vaccines remain undervalued despite their proven safety and benefits, which extend beyond infection prevention to support healthy aging and reduce antimicrobial resistance. To maximize their impact, strategies such as harmonizing recommendations, improving reimbursement, leveraging digital tools, and addressing vaccine hesitancy through better communication and research are essential.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2684962"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating acceptance: challenges and barriers to Nipah virus vaccine uptake in Malaysia's muslim-majority context. 引导接受：在马来西亚穆斯林占多数的背景下，尼帕病毒疫苗接种的挑战和障碍。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-20 DOI: 10.1080/14760584.2026.2674683

Li Ping Wong, Megat Mohamad Amirul Amzar Megat Hashim, Zhiwen Huang, Qinjian Zhao, Hai Yen Lee

{"title":"Navigating acceptance: challenges and barriers to Nipah virus vaccine uptake in Malaysia's muslim-majority context.","authors":"Li Ping Wong, Megat Mohamad Amirul Amzar Megat Hashim, Zhiwen Huang, Qinjian Zhao, Hai Yen Lee","doi":"10.1080/14760584.2026.2674683","DOIUrl":"10.1080/14760584.2026.2674683","url":null,"abstract":"Introduction: The development of Nipah virus (NiV) vaccine offers a vital opportunity for pandemic preparedness in Southeast Asia, especially in Malaysia, where the first outbreak occurred. However, vaccine acceptance must be understood within diverse cultural, religious, and social contexts.Areas covered: This review explores key challenges and barriers to NiV vaccine uptake among Malaysia's Muslim-majority population, drawing insights from past rollouts such as COVID-19 and HPV vaccines. Key issues include religious concerns, misinformation, historical hesitancy, lack of trust in health authorities, and gaps in knowledge, attitudes, and perceptions, which collectively hinder vaccine acceptance and uptake. The paper also highlights enablers namely religious endorsements, transparent communication, and culturally sensitive engagement with trusted healthcare and community leaders. Evidence-based strategies, like motivational interviewing, narrative communication, and tailored outreach, are discussed. Finally, the 7C model is introduced as a structured framework to address behavioral and psychological barriers to vaccination.Expert opinion: Research gaps remain in understanding local psychological drivers, religious governance dynamics, and misinformation patterns. Future efforts should prioritize nationwide KAP studies, validation of behavioral frameworks such as the 7C model, and interventional research on culturally tailored communication. Integrating early halal certification and coordinated religious engagement will be essential for effective and equitable uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2674683"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms. 高度减毒痘病毒作为病毒载体平台的制药生产的最新进展。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-06-18 DOI: 10.1080/14760584.2026.2689611

Linus G Weber, Michael W Wolff

{"title":"Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms.","authors":"Linus G Weber, Michael W Wolff","doi":"10.1080/14760584.2026.2689611","DOIUrl":"10.1080/14760584.2026.2689611","url":null,"abstract":"Introduction: Highly attenuated poxviruses serve as potent viral vectors, oncolytic agents, and therapeutic vaccines. They can accommodate and stably maintain a large genomic payload of foreign inserts. Their limited replication in human cells provides an excellent safety profile, but it concomitantly necessitates higher doses of infectious particles for full therapeutic efficacy.Areas covered: We review recent advances in bioprocesses for the pharmaceutical production of poxvirus-based vectors, focusing mainly on the vaccinia virus and the Orf virus. These include upstream processing using highly permissive cell substrates, optimized feeding strategies, and a virus phenotype that facilitates downstream processing. The study explores ongoing challenges and identifies strategies to adapt the downstream process to intensified upstream processes in order to achieve an economic end-to-end production.Expert opinion: For notably increased virus yields of up to 2 log after amplification, we propose to replace classic adsorption chromatography by a collective and continuous purification platform for separating the virus from process-related impurities. Filtration operations facilitate process scalability while reducing volumes, which is beneficial for a flow-through polishing to meet pharmaceutical quality attributes. Combined with artificial intelligence modeling, these advancements alleviate financial pressures on healthcare systems and accelerate the production of novel vaccine candidates for clinical use.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2689611"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis. 评估西班牙成人呼吸道免疫的社会经济价值：效益-成本分析。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-03 DOI: 10.1080/14760584.2026.2695495

Matthew Napier, Alejandra López-Ibánez de Aldecoa, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Yolanda Moreno, Francisco Mesa, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten

{"title":"Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.","authors":"Matthew Napier, Alejandra López-Ibánez de Aldecoa, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Yolanda Moreno, Francisco Mesa, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2026.2695495","DOIUrl":"10.1080/14760584.2026.2695495","url":null,"abstract":"Background: Vaccine-preventable illnesses, such as pneumococcal disease, respiratory syncytial virus, influenza, and COVID-19, place a significant burden on Spain's population health, health system, and economy. However, uptake and funding constraints limit the full value potential of Spain's national immunization programs.Methods: A benefit-cost analysis was performed to assess the societal return on investment from adult vaccination by estimating benefit-cost ratios and net benefits (NBs). All outcomes were monetized using established methods. Program costs included all direct vaccination-related expenditures. Scenario and sensitivity analyses were performed to assess alternative program specifications and to test the robustness of the model.Results: Spain's age-based respiratory immunization programs generate lifetime societal benefits of €1.9 when monetized mortality risk reduction is age-adjusted, and €7.0 per €1 spent when monetized equally across all ages. This corresponds to NBs of €5.4 to €36.4 billion. Introducing adult RSV vaccination could increase NBs by up to 41-21% compared to the status quo. Additionally, improving uptake across all programs would increase NBs by 134-101%.Conclusions: Spain's adult respiratory vaccination programs generate positive socioeconomic returns. Including adult RSV vaccination and increasing vaccination uptake in general could further increase their societal benefits. Realizing these gains requires adequate public investment to improve vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2695495"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis. 量化法国成人呼吸道疾病免疫接种的社会效益：效益成本分析。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-22 DOI: 10.1080/14760584.2026.2704173

Matthew Napier, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Stéphane Fievez, Yasmine Fahfouhi, Ayoub Boukhlal, Elisabeth Botelho-Nevers, Olivier Guerin, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten

{"title":"Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis.","authors":"Matthew Napier, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Stéphane Fievez, Yasmine Fahfouhi, Ayoub Boukhlal, Elisabeth Botelho-Nevers, Olivier Guerin, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2026.2704173","DOIUrl":"10.1080/14760584.2026.2704173","url":null,"abstract":"Background: Pneumococcal disease, respiratory syncytial virus (RSV), influenza, and COVID-19 place a significant burden on France's population health, health system, and economy. Older adults and adults in clinical risk groups are recommended to receive vaccination against these illnesses, although RSV is not reimbursed.Research design and methods: A benefit-cost analysis was conducted to assess the societal return on investment from adult vaccination by estimating benefit-cost ratios (BCRs) and net benefits (NBs). Health outcomes were monetized using established methods. Program costs included all direct vaccination-related expenditures. Scenario and sensitivity analyses assessed alternative program specifications and tested the robustness of the model.Results: France's age-based respiratory immunization programs generate a BCR of €2.0 to €8.7 per €1 spent over the lifetime, depending on mortality risk reduction monetization. This corresponds to NBs of €9.7 to €72.6 billion. Introducing adult RSV vaccination with a similar uptake to that in the US could increase NBs by approximately 6%-7% compared to the status quo. Achieving aspirational coverage targets across all programs would increase NBs by 138%-175%.Conclusions: France's adult respiratory vaccination programs generate positive socioeconomic returns. Including adult RSV vaccination and increasing vaccination uptake would further increase their societal benefits. Realizing these gains requires adequate public investment.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2704173"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula in the pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19 in the United States. 在美国5-17岁高危儿童中，使用辉瑞- biontech COVID-19疫苗（pp .8.1, 2025-2026配方）接种疫苗对公共卫生的影响

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-31 DOI: 10.1080/14760584.2026.2708203

Alon Yehoshua, Manuela Di Fusco, Abby E Rudolph, Elizabeth Thoburn, Santiago M C Lopez, Josie Dodd, Benjamin Yarnoff

{"title":"Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula in the pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19 in the United States.","authors":"Alon Yehoshua, Manuela Di Fusco, Abby E Rudolph, Elizabeth Thoburn, Santiago M C Lopez, Josie Dodd, Benjamin Yarnoff","doi":"10.1080/14760584.2026.2708203","DOIUrl":"10.1080/14760584.2026.2708203","url":null,"abstract":"Introduction: This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19.Research design and methods: A previously published static decision-tree model was adapted to compare health outcomes with and without vaccination. Demographic, epidemiological, vaccine (effectiveness, vaccine uptake), and clinical model inputs were derived from surveillance data and relevant published studies.Results: In the absence of LP.8.1-adapted BNT162b2 COVID-19 vaccination, COVID-19 burden among those aged 5-11 years and 12-17 years was projected as 1,007,114 and 1,467,724 symptomatic cases, 2,493 and 2,547 hospitalizations, and 109 and 107 COVID-19-related deaths, respectively. Assuming observed 2024-2025 uptake levels of 8.7% and 8.6% among those aged 5-11 and 12-17 years, respectively, LP.8.1-adapted BNT162b2 COVID-19 vaccination was projected to avert 4,387 and 7,146 symptomatic cases, 27 and 31 hospitalizations, and 1 death in each age group, respectively. Increasing uptake to 50% would increase the health burden averted 6-fold.Conclusions: Receipt of an LP.8.1-adapted COVID-19 vaccine was projected to reduce the COVID-19 burden in the high-risk pediatric population, even with low vaccine uptake. Increasing vaccine uptake in this population could yield larger public health impact.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2708203"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025. 2006-2025年各国人乳头瘤病毒疫苗引进的全球政策决定因素。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-22 DOI: 10.1080/14760584.2026.2736328

Jiyeon Suh, Marc Brisson, Emily A Burger, Jane J Kim, Jean-François Laprise, Mark Jit

{"title":"Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025.","authors":"Jiyeon Suh, Marc Brisson, Emily A Burger, Jane J Kim, Jean-François Laprise, Mark Jit","doi":"10.1080/14760584.2026.2736328","DOIUrl":"https://doi.org/10.1080/14760584.2026.2736328","url":null,"abstract":"Background: Although safe and effective human papillomavirus (HPV) vaccines have been available since 2006, national introduction in low- and middle-income countries (LMICs) has progressed slowly. HPV vaccine adoption may have been shaped by evolving World Health Organization (WHO) recommendations, funding policies of Gavi, the Vaccine Alliance, and the disruption from the Coronavirus Disease 2019 pandemic. However, their relative contributions have not been quantified.Research design and methods: This study analyzed policy determinants of national HPV vaccine introduction rate in LMICs from 2006 to 2025, using: (i) generalized linear model (GLM) to assess predetermined policy events, and (ii) changepoint analysis to identify shifts in adoption trends.Results: Across a range of GLMs exploring different events and outcome variables, WHO's one-dose recommendation in 2022 was most strongly associated with an increase in country introductions, with the expansion of Gavi's funding policy for HPV vaccines (2017-2025) also important in some models. Comparing model projections with and without the one-dose schedule yielded an estimated 22.46 additional national HPV vaccine introductions in LMICs. Changepoint analysis identified a significant increase in introductions in 2022.Conclusions: These results quantify the primary global drivers of HPV vaccine uptake, offering actionable insights for expanding equitable vaccine access.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2736328"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differing influenza vaccine uptake and recommendation behavior among healthcare workers in primary health centers, secondary and tertiary hospitals, and schools in a metropolis of southern China. 中国南方某大城市初级卫生中心、二级和三级医院和学校医护人员流感疫苗接种和推荐行为的差异

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-23 DOI: 10.1080/14760584.2026.2736329

Dan'er Lin, Xiangting Zhang, Junxian Hu, Xiaohua Li, Lin Yao, Jianyun Lu, Zhiyun Wang, Yanfang Chen, Yihan Lu

{"title":"Differing influenza vaccine uptake and recommendation behavior among healthcare workers in primary health centers, secondary and tertiary hospitals, and schools in a metropolis of southern China.","authors":"Dan'er Lin, Xiangting Zhang, Junxian Hu, Xiaohua Li, Lin Yao, Jianyun Lu, Zhiyun Wang, Yanfang Chen, Yihan Lu","doi":"10.1080/14760584.2026.2736329","DOIUrl":"https://doi.org/10.1080/14760584.2026.2736329","url":null,"abstract":"Background: Healthcare workers (HCWs) play a key role in recommending influenza vaccination. Few studies have examined HCWs' influenza vaccination and recommendation behavior in China.Research design and methods: A cross-sectional survey was conducted among HCWs in primary health centers, secondary and tertiary hospitals, and schools in Guangzhou, China, in January 2026.Results: Among 3,153 HCWs, 46.2% reported vaccination in at least one of latest four influenza seasons. Average seasonal uptake was 28.2%. Uptake varied by occupation, with higher uptake among public health practitioners (OR = 2.53, p < 0.001) and lower among school healthcare providers (OR = 0.64, p < 0.001), compared with physicians. Knowledge of influenza was negatively associated with vaccination (OR = 0.90, p < 0.001), whereas knowledge of influenza vaccines was positively associated with vaccination (OR = 1.09, p < 0.001) and recommendation behavior (OR = 1.11, p < 0.001). Personal vaccination was positively associated with recommendation behavior (OR = 3.12, p < 0.001). Exploratory generalized path analysis showed knowledge of influenza vaccines was positively associated with recommendation behavior (β = 0.131), mainly through recommendation attitude and personal vaccination, whereas opposite indirect pathways for knowledge of influenza resulted in no significant association.Conclusions: Influenza vaccine uptake remained insufficient among HCWs. Different knowledge domains showed diverse association with vaccination and recommendation behavior. Vaccine-specific knowledge and risk-benefit perceptions were more consistently associated with HCWs' vaccination and recommendation practices.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2736329"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress and challenges of biological reference standards for vaccine quality control and evaluation. 疫苗质量控制和评价生物参比标准的进展和挑战。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-17 DOI: 10.1080/14760584.2026.2734669

Xuanxuan Zhang, Yiping Wang, Fan Gao, Qian He, Zhenglun Liang, Xing Wu, Qunying Mao

{"title":"Progress and challenges of biological reference standards for vaccine quality control and evaluation.","authors":"Xuanxuan Zhang, Yiping Wang, Fan Gao, Qian He, Zhenglun Liang, Xing Wu, Qunying Mao","doi":"10.1080/14760584.2026.2734669","DOIUrl":"https://doi.org/10.1080/14760584.2026.2734669","url":null,"abstract":"Introduction: Advances in the development, manufacture, and testing of biological products, along with the application of the 'Replacement, reduction and refinement,' have driven a paradigm shift in the establishment and application of biological reference standards (BRS) for vaccine quality control and evaluation. Traditional WHO International Standard(s) (IS), historically used for potency harmonization, now face multiple challenges stemming from vaccine diversity, platform complexity, and other factors.Areas covered: This review summarizes recent updates to WHO and other regulatory guidelines on BRS, analyzes 2019-2025 BRS practices of WHO and regional/national regulatory authorities, highlights the need to develop BRS to support the advancement of novel platforms/technologies, and emphasizes harmonized coordination among WHO, regional/national BRS, and manufacturers' in-house quality control working standards.Expert opinion: To ensure that the establishment of BRS could keep pace with vaccine evolution, the following are required: (1) establish rapid-response mechanisms to address emerging pathogens; (2) retain traditional BRS for vaccine quality control and evaluation to maintain traceability of measurement values; (3) develop platform and quality-control BRS for novel technologies; and (4) support manufacturers in developing a product-specific working BRS using Quality by Design (QbD) principles - traceable to phase III protective efficacy.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2734669"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0